hospital covid-19 patient

REGEN-COV lowers risk of COVID-19 hospital stay, death by 71%

Reading now: 231
www.cidrap.umn.edu

Regeneron's combination of two monoclonal antibodies lowered the risk of COVID-19–associated hospitalization and death from any cause by 71% and resolved symptoms and reduced SARS-CoV-2 viral load faster than a placebo, a phase 3 clinical trial finds.In the study, published yesterday in the New England Journal of Medicine, a team led by Regeneron researchers randomly assigned 2,696 adult COVID-19 outpatients at high risk for severe illness to receive either intravenous REGEN-COV or a placebo from Sep 24, 2020, to Jan 17, 2021.REGEN-COV is a 1:1 combination of the monoclonal antibodies casirivimab and imdevimab.Effective regardless of baseline antibody statusOf 1,355 patients given 2,400 milligrams (mg) of REGEN-COV, 18 (1.3%) were

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA